Micar21 help Covid-19 science researchers

Do the SARS-CoV-2 Omicron (B.1.1.529 lineage) detected in South Africa which contains 11 mutations in the receptor binding domain of the spike protein is the most worrying we’ve seen?The first question is whether the variant is more transmissible than the current, prevalent Delta strain. Second will it render our immune defenses — from vaccines and prior infections — less effective (a phenomenon known as immune escape)?

Micar21 started (26 Nov 2021) precise FEP calculations to answer to this question. 
Micar21 Reasearch Timeline SARS-CoV-2 Omicron (B.1.1.529 lineage)

N501Y and K417N Mutations in the Spike Protein of SARS-CoV-2 Alter the Interactions with Both hACE2 and Human-Derived Antibody: A Free Energy of Perturbation Retrospective Study
Link to Journal of Chemical Information and Modeling

The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: A Free energy of perturbation study
Link to bioRxiv

The R346K Mutation in the Mu Variant of SARS-CoV-2 Alter the Interactions with Monoclonal Antibodies from Class 2: A Free Energy of Perturbation Study
Link to bioRxiv

Micar21 is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (own Pipeline). Micar21 focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET:

Entire drug discovery process takes 2-8 weeks through Micar21 Drug Discovery platform

Micar Innovation novel molecules has non-clinical Proof-of-Concepts achievements in therapeutic areas such as neuroscience, oncology, cardio-vascularity, dermatology, immunology (Pipeline). The business model is based on licensing our intellectual property to commercial partners or on the creation new spin out companies. The demonstration of true clinical proof-of-concept is a key value-creation step in the clinical development of a medicine.

Micar Innovation received the CIDIC award for its well-chosen positioning in a complex and long value chain, where it can create key-value contributions by delivering non-clinical POCs. The company can be qualified as a fountain of intellectual property and an IP broker for new pharma startups and big pharma industry.

In computer-aided drug design (CADD), the ultimate goal is to be able to predict accurately how strongly a potential drug compound will bind to a protein target (i.e., the compound’s binding affinity). Micar21 Drug Discovery platform able to do this, drug discovery to be significantly accelerated, since we would only need to synthesize in the lab those compounds with predicted high affinity for the target of interest (and predicted low affinity for proteins we didn’t want to interfere with).

Discover our Pipeline

We have our own drug discovery programs and our lead compounds are already in Drug Discovery & Preclinical studies. Our strategy is to develop drug for both: humans and companion animals.
*It takes about 7-12 months to obtain a license for companion animals drug.